By Willem Kools, Ph.D.
As biopharmaceutical projects occupy an increasingly larger share of the development pipeline, drug makers are striving to implement strategies that bring affordable therapies to market quickly and cost effectively. Over the past several years, the adoption of singleuse technology has emerged as one important strategy for improving downstream and upstream processing while avoiding the downsides of traditional stainless-steel bioreactors.
Uptake of single-use technology shows no signs of slowing. A recent market report predicted the single-use market will become a $6-billion industry by 2024, marking a compound aggregate growth rate of 11.1% from 2015 to 2024.1
While drug companies are highly motivated to use single-use solutions to speed the development of new molecules, increase production efficiency, and decrease capital expenditures, they still face several complicated challenges such as n-time delivery of materials, regulatory issues, and quality questions. How are innovators addressing these issues and bringing single-use solutions to the next level?